'Amytrapper', a Novel Immobilized Sepharose API Matrix, Removes Amyloid-β from Circulation in vitro

Area of Science:

• Neuroscience
• Biochemistry
• Biotechnology

Background:

• Alzheimer's disease (AD) is a leading cause of dementia, characterized by amyloid-beta (Aβ) accumulation.
• Current therapies targeting Aβ production have limited success, necessitating novel approaches.
• Recombinant Technologies LLC (RTL) developed Amytrap peptide to clear Aβ from circulation.

Purpose of the Study:

• To develop and validate a prototype device, 'Amytrapper', for extracorporeal Aβ clearance.
• To assess the efficacy and specificity of Amytrapper in removing Aβ.

Main Methods:

• The Amytrap peptide (active pharmaceutical ingredient) was conjugated to a sepharose matrix using click chemistry.
• Amytrapper's ability to remove Aβ42 from media, sera, and plasma was tested.
• Binding specificity was confirmed through pre-blocking, SDS-PAGE, and quantifying bound/unbound Aβ42.

Main Results:

• Amytrapper successfully removed Aβ42 from spiked media and biological samples (sera, plasma).
• Binding was specific, as demonstrated by competitive inhibition assays and SDS-PAGE analysis.
• The study provides proof of concept for the Amytrapper device design.

Conclusions:

• Extracorporeal clearance of Aβ42 using Amytrapper is a viable strategy for managing amyloid accumulation in Alzheimer's disease.
• Amytrapper represents a potential new therapeutic modality for disease modification in AD.